Journal of Bioanalysis & Biomedicine

Dr Florence Raynaud graduated in pharmacy from the University of Paris V where she carried out an MSc in pharmacochemistry. She pursued a PhD in neuroscience at the University Louis Pasteur in Strasbourg, and has been working at The Institute of Cancer Research since 1992. Dr Raynaud has been involved in the preclinical development of 20 compounds that were synthesised at the ICR and nominated for clinical development. These include platinum agents, antimetabolites, signal transduction pathway inhibitors, and antihormonal agents (including abiraterone).Her interest lies in optimising the pharmaceutical properties of new agents to improve their administration schedules.